• Am J Health Syst Pharm · Nov 2010

    Review

    Unlabeled uses of factor VIIa (recombinant) in pediatric patients.

    • Irene Hong and Joan Stachnik.
    • School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, NY, USA. irenehon@buffalo.edu
    • Am J Health Syst Pharm. 2010 Nov 15;67(22):1909-19.

    PurposeUnlabeled uses of factor VIIa (recombinant) in pediatric patients are reviewed.SummaryFactor VIIa (recombinant) is currently approved for the treatment and prevention of bleeding in patients with hemophilia A or B and inhibitors of coagulation factors, acquired hemophilia, or congenital factor VII deficiency. Use of this agent has expanded to include unlabeled indications, including bleeding unrelated to coagulation factor deficiencies in infants, children, and adolescents without congenital hemophilia. Results of a search of the English-language medical literature for relevant articles primarily included case reports and retrospective reviews, with few randomized clinical trials. Reasons for use of factor VIIa (recombinant) included bleeding associated with acquired coagulopathies or congenital disorders resulting in coagulopathies, hepatic failure, surgery, and bleeding associated with prematurity, malignancies, and trauma. In most reports, conventional therapies were used with limited or no success. Factor VIIa (recombinant) was most commonly used in patients with coagulopathies or hemorrhage secondary to surgical procedures, primarily cardiopulmonary bypass and liver transplantation, as well as intracranial hemorrhage. In general, higher mortality rates were reported in medical versus surgical patients. The lowest rates of complete response were seen in younger patients and patients with trauma. A decrease in the requirement of blood product transfusion after the use of factor VIIa (recombinant) versus standard therapies or placebo was commonly observed but was not statistically significant in many cases.ConclusionGiven the lack of well-designed controlled studies, current evidence is inconclusive regarding the safety and efficacy of factor VIIa (recombinant) for unlabeled indications in pediatric patients.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…